Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Metrics to compare | ASBP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipASBPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −3.8x | −0.6x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | −0.4x | 3.4x | 2.6x | |
Price / LTM Sales | 2,616.3x | 18.4x | 3.4x | |
Upside (Analyst Target) | - | 69.6% | 41.5% | |
Fair Value Upside | Unlock | −14.8% | 4.4% | Unlock |